Trial Profile
Phase 1 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs TTC 352 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors TTC Oncology
- 12 Jan 2021 Results presented in a TTC Oncology media release.
- 08 Aug 2020 Status changed from active, no longer recruiting to completed.
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium